STRO.NASDAQSutro Biopharma, INC

Form 4: Sutro Biopharma CFO Edward Albini Reports Stock Transactions

Sentiment:

SEC Form 4 Filing

📋All filings for Sutro Biopharma, INC
🔒Login to Follow

CFO Edward Albini reports the vesting and tax withholding of Sutro Biopharma stock.

Summary

  • On March 4, 2025, Edward C. Albini, CFO and Secretary of Sutro Biopharma, Inc., reported transactions involving the company's common stock and Restricted Stock Units (RSUs).
  • Albini acquired 9,125 shares of common stock through the vesting of RSUs.
  • 3,748 shares were withheld by the issuer to cover income tax obligations related to the RSU settlement at a price of $1.42 per share.
  • Following these transactions, Albini directly owns 126,925 shares of Sutro Biopharma common stock and 9,125 RSUs.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing reflecting standard compensation practices; therefore, the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices involving stock-based compensation.

Stakeholder Impact

  • The transactions have a minor impact on shareholders as they reflect standard executive compensation and tax withholding.

Key Dates

DateDescription
03/04/2023RSUs vest as to 1/4th of the total award annually beginning on this date.
03/04/2025Date of the reported transactions: RSU vesting and tax withholding.
03/04/2026Expiration date of the Restricted Stock Units.
03/06/2025Date of signature for the Form 4 filing.

Keywords

Form 4, Sutro Biopharma, Edward Albini, Stock, RSU, CFO, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.